四川百利天恒药业股份有限公司 关于发行H股并上市的进展公告

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is progressing with its plan to issue H-shares and list on the Hong Kong Stock Exchange, but has decided to delay the global offering and listing due to current market conditions [1][2]. Group 1 - The company has published its H-share prospectus and details regarding the public offering on November 7, 2025 [1]. - The subscription for the H-shares is limited to qualified overseas investors and certain domestic institutional investors as per relevant regulations [2]. - The company will not publish the announcement on domestic stock exchanges or media, and relevant information can be accessed on the Hong Kong Stock Exchange website [2].